CRI provides essential funding for immunotherapy research that has led to the adoption of many treatments helping cancer veterans like myself benefit from extended survival and quality of life. Moreover, CRI has numerous resources to help cancer patients, including informative patient summits, clinical trial navigators and an amazing group of ImmunoAdvocates sharing their experiences. As an ImmunoAdvocate, CRI has provided me with the opportunity to reach out to the wider cancer community to convey information, explain the benefits of immunotherapy and, most importantly, support patient advocacy on an individual and collective basis. As such, CRI has not only benefitted me by funding the research that has allowed me to survive, but has also provided me with a forum and a community to allow me to work together with so many others in order to imagine a future immune to cancer.
CRI has a mission to save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer.
As an ImmunoAdvocate via CRI I have been lucky enough to work with/along side them as they continue to advance the conversation and community of cancer battlers and survivors.
CRI has been the most important source outside of NIH itself for funding research in cancer immunology and specifically for supporting emerging leaders in the field through their postdoctoral fellowship training and during their explorations of high-risk, high-reward work in their early- to mid-career faculty positions. CRI's impact now extends to brokering collaborative work between multiple pharmaceutical companies and multiple academic groups. CRI deserves enormous credit for the emergence of immuno-oncology as one of the leading frontiers in contemporary biomedicine.
Thank you so much for the great support CRI has offered to all post-doctoral fellows. It is the support that advances the next generation scientists who will revolutionize cancer treatment.
CRI is a remarkable organization founded on the premise - long ignored by other cancer foundations - that the immune system is capable of combating cancer. Recent developments in cancer immunotherapy have proved, spectacularly, that this premise is correct. CRI funding has helped the careers of many brilliant young scientists and it has been a pleasure to be involved in the process of reading and evaluating some of their applications
By supporting some of the best young minds in the world to perform basic research on the immune system and cancer, CRI has long had and continues to have a huge positive impact on science and medicine. We never know whether the next great discovery, like immune checkpoint inhibitors, might come from. By funding young scientists in some of their most creative years to perform high risk-high reward research, CRI primes the engine of transformative discovery.
CRI has most adamantly believed in the power of our immune system in the "war on caner" for decades. CRI's generous support of cutting-edge tumor immunology and basic immunology research has transformed, and will continue to transform the landscape of cancer therapies .
CRI is an amazing cancer research foundation that really makes an impact on supporting cancer immunology research, which is the LEADING EDGE of cancer therapies right now. They invest in the next generation of scientists and the CRI postdoctoral fellows are some of the best in the world, working on some of the newest frontiers of immuno-oncology. I am a cancer immunologist at the Salk Institute and with CRI's support our lab has been able to develop entirely new ways of thinking about the connections between metabolic regulation of cancer and immunity as well as how cancers develop resistance to cancer therapies aimed at stimulating our immune system.
CRI almost single handedly kept the flame of cancer immunotherapy alive while the NCI, AACR and most other cancer charities/funders ignored it. It has been, and remains, an essential organization for research funding, education, outreach, and scientific advance.
I'm proud to have served as an advisor to CRI during the process of judging candidates for CRI post-doctoral fellowships. The panel of advisors are outstanding scientists from across the country who meet twice a year to review fellowship applications. These applications are from fabulous young scientists (usually recent Ph.D recipients) eager to receive training in basic, translational or clinical research. The CRI has supported post-doctoral fellows performing so much of the research leading to the current successes in turning the immune system against cancer. Having seen first-hand how well the fellowship selection process functions, I am also proud to make my own annual financial contribution to the CRI. It is such an outstanding organization.
Thanks to CRI, and the funding they provide for numerous clinical trials for immunotherapy, I am alive. The care and attention this organization provides to help researchers study immunotherapy in treating cancer means the clinicians who minister to patients have options in cancer care that are more effective than ever before.
I was fortunate to participate in a clinical trial using immunotherapy drug Keytruda to treat my stage 4 ampullary cancer. With the prognosis near certain death, the immunotherapy cured the cancer in months.
My experience in supporting CRI since my cure has been exemplary and I wholeheartedly support them in every way I can.
Cancer Research Institute has top-level senior scientists in cancer and immunology fields to steer funding towards researchers and projects that have high potential to make new breakthroughs in cancer immunotherapy. Thank you, CRI !
The Cancer Research Institute (CRI) is an amazing organization that provides me with an unparalleled platform to conduct my research in cancer immunotherapy. In addition, CRI has given me a great opportunity to reach out to and collaborate with other outstanding scientists in this field. Importantly, as an international postdoc, I am most grateful for CRI’s decision to support merit-based research for scientists with diverse backgrounds or nationalities. Thank you CRI!
The Cancer Research Institute is an amazing organization that provides critical support to both basic and translational research aimed at harnessing the immune system to fight cancer. Funding from the CRI has been integral to my postdoctoral research and has further fueled my passion for cancer immunotherapy. For this, I am extremely grateful and would like to thank the CRI and its many donors for their continued dedication and support to young immunologists and the field of cancer research.
Curing cancer is my dream. I have had the great fortune to receive support from the Cancer Research Institute (CRI) and work as a postdoctoral researcher at Massachusetts General Hospital and Harvard Medical School. The generous support from CRI provides me an extraordinary opportunity to explore how the immune system fights tumors and develop novel strategies to overcome resistance to current therapies, and most importantly, bring hope to cancer patients! Thank you, Cancer Research Institute!
I am an early career scientist focusing on tumor immunity. CRI provides essential support for my research. In addition to financial support, CRI provides numerous opportunities for training and collaboration. I am thrilled to be a part of the CRI community.
I am an early career scientist with a research interest in tumor therapy. CRI has provided essential support to help me establish an independent research program and explore new research directions. The application process for CRI funding is straightforward. In recent years, with limited federal funding, financial support from nonprofits, such as CRI is critical for the discovery of new therapies for cancer patients.
The Cancer Research Institute has been funding postdoctoral fellows in my laboratory for a number of years now and I am very grateful for their contribution to my research. The peer review process for their fellowship and grant programs is very rigorous and their support is amazing. The support CRI provides to Fellows to collaborate and network in the broad field of immunological and cancer research is crucial for their career development.
The vision CRI had when starting to promote the involvement of the immune system in cancer research is truly remarkable and has led to several breakthroughs in the way we treat this devastating disease.
I'm a young scientist who is eager to help fighting cancers by doing basic research. With a three-year postdoctoral fellowship from Cancer Research Institute, I’m hoping to dissect the complexity of signaling in the tumor environment and help improve therapeutics for all cancers. I really appreciate CRI's generous support in cultivating the future of cancer research, and its effort bringing the fruit of science to the patients.
As a CRI-sponsored post-doctoral fellow, CRI is playing critical roles in my scientific career. CRI does not only provide me with a stipend, but also exposes me to great ideas from other fellows and senior scientists during the annual conference. Cancer is still a devastating disease, but the CRI community is trying best to conquer cancer.
Thanks to the Cancer Research Institute, I've been awarded with essential funding to research essential aspects of cancer biology. I'd like to highlight, that they fund translational research as well as basic research. This demonstrates that their criteria to select grantees are based on expert scientific views. Thank you for many discoveries to come!
I am an Australian cancer immunology research scientist and The Cancer Research Institute has funded my research on and off for more than a decade. Their funding is peer reviewed and well considered across many programs, including those funding early career scientists. They were responsible for the annual meetings in this area of research since 2000 and I met virtually all of my most important collaborators from all over the world in the field at these meetings. Their web site has been one of the best public educational tools in the field. Their leadership has been brilliant and their staff loyal, friendly and helpful over all of those years. In summary they have greatly enriched my career and provided the world great service.
CRI is a big support for my postdoctoral research. I am studying the gene regulatory network of T cell development, which is essential to understand cancer immunobiology. Without the funding from the CRI, I would not be able to fully focus on the factors that I am working now. I am so grateful for CRI's work to support basic science and translational researches!
CRI was the FIRST charity to dedicate their mission to advancing engaging the immune system to fight cancer. They have supported hundreds of young scientists and physicians to bring them into this field that has transformed cancer therapy. An absolutely amazing organization that is totally dedicated towards curing cancer using your own immune system.
CRI funding has been transformative for the field of cancer immunotherapy and is driving major innovation in the field. Our lab's funding from CRI is enabling us to take big risks and push forward in new directions that we hope will continue to expand the reach of immunotherapies to treat cancers that are not yet responding to therapies. I am profoundly grateful for CRI's tireless work to promote fundamental inquiry and clinical translation of immunotherapy.
The Cancer Research Institute (CRI) is an amazing nonprofit offering a plethora of Immunotherapy resources to gain knowledge, stay updated, seek Clinical Trial offerings and to connect with fellow cancer patients/caregivers/medical personnel. CRI funds promising Immunotherapy research that is changing the cancer treatment landscape and is saving and changing lives. Knowledge is power and as a Patient Advocate, I have been fortunate to participate as a Patient Speaker and attend several of their annual Immunotherapy Patient Summits. I am always in awe of the Researchers and Doctors asked to share their work at the Patient Summits. Knowledge, Hope, Inspiration and Support is transpired to all those that attend the annual Patient Summits. I applaud CRI for all that they do and for funding Immunotherapy Research so that I could still be here alive today!
Cancer Research Institute is the oldest non profit organization focusing on immunotherapy and funds the best scientists in the field . By sharing my story and experience with immunotherapy CRI has given me a chance to give back and share hope with other patients. Their Immunotherapy Patient Summits are free educational events that give patients access to experts in the field and advocates who have been treated with immunotherapy. Knowledge is empowering when faced with a cancer diagnosis. Clinical trial navigators are available to assist patients in discovering trials that may benefit them. Cancer Research Institute is a trusted source of information for patients who want to learn more about immunotherapy and it’s potential.
CRI sponsored my lab's research looking into how tumor hypoxia (low oxygen concentration) created a barrier that helped make prostate and pancreatic cancer almost totally immune to the FDA-approved immunotherapy antibodies. This critical support and lead-of-faith from CRI in believing in our work when others did not allowed us to 1) generated critical pre-clinical data to secure a larger grant, 2) published a high-impact paper describing how ablation of hypoxia sensitized prostate cancer to immunotherapy, and 3) eventually launch a clinical trial in which prostate and pancreatic cancer patients are now benefiting from this approach. Thank you CRI for helping us all engage the immune system to wipe out cancer!
The ambition and dedication of CRI in addressing the most urgent questions in the field of cancer immunology and immunotherapy have made a difference to the world. I am very grateful to be supported by CRI to pursue an exciting career in the field and be part of the excellent community.
I am an early-career scientist with a strong interest in understanding how tumors evade the immune system during cancer progression and metastasis. The Cancer Research Institute has been on the forefront of immunotherapy research, and decades of work have paid off with exciting results with new immunotherapy treatments. However, not all tumors respond to immunotherapy, and metastasis remains a leading cause of cancer death. The Cancer Research Institute has directly supported my work on understanding how pancreatic cancer regulates the immune system to allow for tumor growth and the spread of the disease. This work has the potential to provide key insights into strategies for activating an anti-tumor immune response. Thank you, Cancer Research Institute!
I am a postdoctoral researcher fortunate to have been supported by the CRI Irvington Postdoctoral Fellowship. It is truly commendable that CRI recognizes the value of basic immunological research, and that it is committed to supporting young researchers like me who are pursuing these questions.
I hope those comprising CRI are interested in 2lbs of stevia curing my uncle's 6 in transition phase to cancer breast tumors. He'd just lost his prostate to cancer, and thought his life was over. Adding the facts 62lbs of flab melted off with no hanging/flabby skin, and type 2 diabetes no longer registering makes this seem like a fairy tale, but those results did happen.
Stevia is very high in alkalinity, I've read that a high alkaline diet= a difficult environment for cancer and other diseases from living inside those bodies, and am hoping that someone at CRI is interested in investigating these valid claims.
I am a postdoctoral scientist at Harvard Medical School, studying how the immune system reacts to insults by infections and cancer. CRI is funding my research since the beginning of this year and I am very grateful for this. It is a great honor for me to get awarded a CRI fellowship, which is well-known as a very prestigious fellowship. CRI recognizes the necessity to fund basic research in order to advance the clinic.
As a CRI-funded postdoctoral fellow, I could speak all day about the tireless efforts of the CRI to fund basic and translational research and bring immunotherapy to the clinic. The most significant thing for me is that the CRI awards grants based on scientific merit, regardless of nationality or location of research. Which means that they funded me (a non-American citizen/non-permanent resident) to do cancer research in France. I am greatly indebted to the CRI and its donors for believing in the value of my research, and will continue to work my tail off throughout my career to make their early investment in me a worthwhile one. Thank you CRI!
CRI has played a significant role in my career as a young scientist by funding three years of my postdoctoral research at Caltech. In addition to direct support, I have greatly enjoyed the opportunities CRI has provided to network and collaborate with scientists involved in a very broad range of immunological and cancer research. They do a great job of bringing everyone - from basic researchers to clinicians - to the same table to address really important problems.
The CRI has played an integral part in my development as a scientist and cancer researcher. The organization is perceptive enough to still fund high risk though highly rewarding research. I was lucky enough to receive a postdoctoral research fellowship from them this year to study how intestinal bacteria affect the progression of colorectal cancer using advanced chemical techniques. It is an honor to be included in the outstanding research that is funded and supported by the CRI. A true gem in the cancer research field!
The CRI is supporting my project this year, in which we are trying to develop new strategies for cancer immunotherapy. It's such an honour for me, especially knowing that Lieping, one of the major contributors to the newly breakthrough in immunotherapy, was also supported by the CRI in his early years. The work CRI has supported proves that they have done a really great job in pushing the researches in cancer forward during the past decades.
The CRI began funding my post-doctoral work this year. This has allowed me to work on understanding the immune response to metastasis, however, through the events the CRI runs they have also allowed me to network with other young cancer immunologists producing numerous contacts and potential collaborations which will help move this work forward.
More than 15 years ago I had been very lucky to receive a research fellowship from CRI. That support turned out to be very important in allowing me to finish a study that became my modest contribution to the knowledge of differences in gene regulation between mouse and human immune cells. Later on, I became involved in an educational program in tumor immunology in Moscow, Russia. Due to generous CRI support, we were able to invite very best scientists to come to Moscow specifically for teaching. Many students of that program are now successful young researchers advancing the flourishing field of tumor immunology. Over the years I have attended several CRI symposia and had the privilege of personally meeting a number of CRI administrators and employees including its late scientific director Dr.Lloyd Old. I think Dr.Old was an absolutely great scientist and visionary, and all the members of his team are highly professional bright people dedicated to fighting cancer using immunity. CRI is continuing to do a magnificent job in helping cancer immunology research.
Is a researcher in the field of oncoimmunology, I constantly give CRI top rating for its focused and flexible support and high quality of research and educational programs funded by this remarkable organization. My opinion is based on a number of attempts (both successful and not) to obtain funding from CRI, as well as on impressions from participation in a number of CRI meetings.
The CRI has supported me as a budding researcher in the field of cancer immunotherapy over the past two years. Beyond funding my research in the lab, the CRI has coordinated my interactions with scientists and physicians to inspire new cutting-edge ideas. The CRI also helps to eliminate the disconnect between scientists and patients by setting up meetings with immunotherapy recipients, allowing us to truly see and feel the effect we are having on so many lives. The payoff for their efforts has been fully realized in the last decade, with cancer immunotherapy (their primary focus) being recognized as the Science magazine breakthrough of the year in 2013.
The CRI has been at the forefront of cancer immunology research for decades. The growing success of cancer therapies aimed at the immune system is in no small part due to the efforts of the CRI. As a fellow with CRI funding, I am very grateful for their support, which is allowing me to hone my immunology training for a career in cancer immunology. This organization is not simply a distributor of cash, however. I have been struck by the enthusiasm and optimism of the CRI staff (scientific or otherwise), their desire to engage the public to increase cancer awareness, and their ability to foster a highly collegial environment that is unsurpassed by any other nonprofit I've interacted with. The CRI is doing a great job, and I'm proud to be one of their fellows!
CRI has consistently funded the best people in cancer research to do ground breaking translational research in cancer, and has also provided a cutting edge forum for many years for discussion of the now clearly useful field of cancer immunology.
The research CRI is currently founding has the potential to save many lives and to greatly increase the knowledge of mechanisms underlying the interplay between tumor cells and the immune system. They are definitively doing an amazing job.
I have been supported by CRI postdoctoral fellowship since 2013, just like hundreds of other researchers CRI supported for decades. Thanks to their efforts, promising immune therapies and drugs have been greatly developed in cancer treatment. Although my research is not directly on clinical, the annual symposium provides great opportunity for me to learn about the latest progress on cancer therapies. Sharing researches with clinicians and other CRI fellows inspire novel ideas and facilitate collaborations.
I am a post-doctoral scientist at UCSF who's research is supported by CRI, for which I am very grateful. I have been extremely impressed with the breadth of research funded by CRI and I firmly believe that CRI does an outstanding job of advancing the treatment of human diseases though advances in basic biology.
Great institute to really support research that makes a difference in cancer diagnosis and treatment. I appreciate the research funds given by CRI to allow us to tackle the immune system for cancer treatment.
I am supported by CRI as a postdoctoral researcher at the University of California, San Francisco. I was ecstatic to start work that will help us learn more about tumor-related inflammation and the damage it can cause. I recently had the opportunity to attend a CRI meeting in New York and was astounded by the quality of work that CRI supports across the country and the passion with which these researchers tackle problems central to cancer treatment. I would encourage you to support this fantastic organization. Thanks!
As a cancer researcher, I highly endorse the fantastic work done by the Cancer Research Institute (CRI). The CRI is the premier non-profit organization in the realm of cancer immunotherapy, which can lead to durable responses not seen using other therapeutic approaches. (For this reason, cancer immunotherapy was recently highlighted as the Breakthrough of the Year for 2013 by the prestigious journal Science.) In addition to organizing clinical trial information for patients and hosting a fantastic biennial conference for scientists, the CRI funds exceptional trainees and cutting-edge research in order to work towards a cure for cancer. Independent analysis by Charity Navigator reveals that the CRI has earned the top four-star rating, scoring 94% on financial and a perfect 100% on accountability and transparency (http://www.charitynavigator.org/index.cfm?bay=search.summary&orgid=3417#.VEAryktUBD4).
I am a graduate student at the University of California - Berkeley. My doctoral work focuses on the role of the immune system in fighting cancer. In Sept 2013, I was awarded a fellowship from the CRI to fund my research. This fellowship has allowed me the academic and financial freedom to pursue research directly related to human disease.I cannot speak highly enough of the CRI's work. The CRI has supported hundreds of scientists in the fight against cancer through direct research funding. In addition, the CRI organizes various annual symposia to allow scientists and clinicians to share research and discuss collaborative projects. Through these activities, the CRI has made a wonderful contribution to the field of cancer research, and it's work has had a direct impact on the development of novel, promising therapies for the treatment of cancer.
Funding from the CRI allows me to conduct a clinical trial in late stage cervical cancer patients that otherwise have little hope for a cure.
I am a post-doc at The Rockefeller University, and receives CRI post-doc fellowship. The funding from CRI greatly helps my ongoing research in the field of cancer and immunology. Myself also benefits greatly from attending the events organized by CRI, such as the annual international cancer immunotherapy meeting. These events greatly broaden my scientific horizon and provide the changes to collaborate with other scientists in the field to do great science together!
The Cancer Research Institute (CRI) has funded my research as a postdoctoral fellow at the University of Washington since 2013.
The CRI has supported my postdoctoral research since 2012 through one of their competitive fellowship awards. Thanks to this amazing support we have developed new therapeutic strategies to re-direct the immune system against aggressive malignancies such as ovarian cancer. Transforming devastating cancers into curable diseases will only be possible through immunotherapy, and the CRI is substantially leading this vital task.
I was awarded a CRI fellowship to conduct my research at the University of Pennsylvania. This incredibly generous support for basic research that has really laid the foundation for my postdoctoral career, and has allowed me to focus on developing as a scientist. This funding will allow our research team to further develop our basic understanding of how immunotherapy works in cancer, which will hopefully continue to shape the way we approach this therapy in patients.
They give me very good support on my research and are together with me all the time. With the help from them, I made good progress with my research, which provides further understanding of B cell lymphomas.
I was awarded CRI fellowship to conduct my research at the University of Chicago. This helped us to identify pathways critical to leukemias and lymphomas.
CRI's generous and continued support of our research in cancer immunology and cancer immunotherapy helped us to establish a sustainable clinical research and teaching/training program in the field. New students and young researchers were introduced to the field as MD/PhD students and young faculty. CRI's CVC helped to establish a Clinical Trials Center at the University of Zurich. Ultra-lean management and great communication skills with an outstanding scientific faculty advising characterize CRI's success as a non-profit organization focused on Cancer Immunology and Cancer Immunotherapy.
I was awarded a CRI postdoc fellowship a few years ago, which turns me from a scientific worker to a scientist. The critical difference between these two is that the later endowed with a great passion and motivation for research which grew in me during this postdoctoral training phases. Without the support from CRI, this transformation will not likely happen. Thank CRI for training young people in the cancer research field, and I believe our research will eventually provide great benefits for cancer patients.
During my postdoctoral studies at the section of Immunobiology at Yale Medical School I have been a CRI fellow studying the transcriptional regulation of cytokine genes driving the differentiation processes of T helper cells. During that period, and having peace of mind because CRI was funding my research, we were able to advance our knowledge about gene regulation and show that the three dimensional structure of the genome affects the expression profile of a locus. More importantly others have shown that proximity of gene loci in the 3D nucleus increase the probability for a translocation event usually found in leukemia and tumors.
The funding I have received during my postdoctoral studies was of fundamental importance and helped me get an Assistant Professorship. And again my good angel CRI was there to support my research with an Investigator award. This gave a kickstart to my career and my first steps as an independent investigator. I am really proud being part of this team of people who are dedicated and hard working with the ultimate goal of conquering cancer.
I was the recipient of a CRI postdoctoral fellowship award that funded my research in the function of the innate immune system during aging at MIT. Because of the generous support of CRI, I was able to make important discoveries that I anticipate will help to form the foundation of further study in age-dependent dynamics of signaling pathways that regulate the immune response later in life. Throughout my years as a CRI fellow, I have found the staff at CRI to be professional, supportive, and truly dedicated to the cause of advancing scientific knowledge toward the goal of eliminating cancer. My heartfelt thanks goes to CRI, and I would strongly recommend CRI as a benefactor of those seeking to support biomedical research.
The Cancer Research Institute by wisely selecting and generously supporting investigators and projects on cancer research has immensely contributed to advance our understanding of malignancies, thus paving the way for novel therapies. With the support of the CRI we have developed new MHC-peptide based reagents that allow improved detection and isolation of antigen-specific CD8+ and CD8+ T lymphocytes. We endeavour after final optimization to make these reagents generally available, thus contributing to better monitor and understand cancer specific T cell immunity.
Twenty five years ago I received a posdoctoral fellowship from the CRI. This allowed me to get an unvaluable training in the field of cancer immunology that was the start of my scientific career. CRI did not mind the fact that I was a young physician just arrived in the US, and generously funded my research. CRI is the perfect example of a phylantropic organization in the frontier of new knowledge and humankind. I am now a top administrator of one of the largests European Universities and I remain grateful to CRI for their support.
As a former recipient of Cancer Research Institute postdoc fellowship, I am very grateful to CRI for the generous support to allow me to carry out frontier research work in chemical biology at Harvard University. It was an eye opening experience that not only broadened my understanding at the interface of chemistry and biology, but also gave me an inspiration to choose my own research topic related to cancer and immunology. In my independent academic work, I have benefited tremendously from that postdoctoral experience and I am glad I have made the right decision to develop new anticancer drugs.
In 2008, the Cancer Research Institute was the only agency that was
willing to fund a risky project whose objective it is to understand
why the immune system fails in the elderly. Since then, this study has
yielded exciting results on how aging of stem cells influences immune
function and we are currently preparing two manuscripts on our work.
We have recently procured a grant by the National Institute on Aging,
totaling $658,000, to follow up on these results. Obviously, we would
not have been able to undertake this project without the visionary
support of the Cancer Research Institute.
I was a recipient of funding from the CRI to conduct my postdoctoral research and I am a yearly donor to this institute. I am very positive about the CRI and their mission because they get results. They understand the process of discovery and innovation well enough to invest in basic research of the immune system because the findings that come from such basic studies are the building blocks of translational research. And, they have the vision to support efforts to take key basic findings from the bench to the bedside. A key case in point is the development of the immunotherapeutic drug Ipilimumab, which the CRI helped advance, as a treatment for melanoma.